Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9587-92. doi: 10.1073/pnas.1610099113. Epub 2016 Aug 1.

Abstract

The aggregation of α-synuclein (aSyn) leading to the formation of Lewy bodies is the defining pathological hallmark of Parkinson's disease (PD). Rare familial PD-associated mutations in aSyn render it aggregation-prone; however, PD patients carrying wild type (WT) aSyn also have aggregated aSyn in Lewy bodies. The mechanisms by which WT aSyn aggregates are unclear. Here, we report that inflammation can play a role in causing the aggregation of WT aSyn. We show that activation of the inflammasome with known stimuli results in the aggregation of aSyn in a neuronal cell model of PD. The insoluble aggregates are enriched with truncated aSyn as found in Lewy bodies of the PD brain. Inhibition of the inflammasome enzyme caspase-1 by chemical inhibition or genetic knockdown with shRNA abated aSyn truncation. In vitro characterization confirmed that caspase-1 directly cleaves aSyn, generating a highly aggregation-prone species. The truncation-induced aggregation of aSyn is toxic to neuronal culture, and inhibition of caspase-1 by shRNA or a specific chemical inhibitor improved the survival of a neuronal PD cell model. This study provides a molecular link for the role of inflammation in aSyn aggregation, and perhaps in the pathogenesis of sporadic PD as well.

Keywords: Parkinson's disease; aggregation; caspase; inflammasome; synuclein.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alum Compounds / pharmacology
  • Caspase 1 / genetics*
  • Caspase 1 / metabolism
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Dipeptides / pharmacology
  • Gene Expression Regulation
  • Humans
  • Inflammasomes / metabolism*
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Lewy Bodies / drug effects
  • Lewy Bodies / metabolism*
  • Lewy Bodies / pathology
  • Lipopolysaccharides / pharmacology
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neurons / pathology
  • Nigericin / pharmacology
  • Protein Aggregates / genetics*
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Signal Transduction
  • Vitamin K 3 / pharmacology
  • alpha-Synuclein / chemistry
  • alpha-Synuclein / genetics*
  • alpha-Synuclein / metabolism
  • para-Aminobenzoates / pharmacology

Substances

  • Alum Compounds
  • Dipeptides
  • IL1B protein, human
  • Inflammasomes
  • Interleukin-1beta
  • Lipopolysaccharides
  • Protein Aggregates
  • RNA, Small Interfering
  • SNCA protein, human
  • alpha-Synuclein
  • para-Aminobenzoates
  • belnacasan
  • aluminum sulfate
  • Vitamin K 3
  • Caspase 1
  • Nigericin